title: Treatment of lipid disorders in obesity.
abstract: Obesity is the most common cause of secondary hyperlipidemia. Atherogenic dyslipidemia refers to elevated triglycerides, low HDL-cholesterol and small dense LDL associated with visceral obesity and metabolic syndrome. Obesity may also be associated with isolated low HDL-cholesterol or high triglycerides and postprandial hyperlipidemia. While some obese patients have high LDL cholesterol concentrations, obesity has a more pronounced effect on other atherogenic lipids and lipoproteins. Obesity may aggravate familial lipid disorders. Lipid disorders in obesity are responsive to weight loss, pharmacotherapy and weight loss surgery. Statins are the lipid-lowering drug of choice, together with lifestyle change. Hard clinical end point data to support combinations of statins with other drugs is lacking. After weight loss surgery, the absolute risk of cardiovascular disease should be reassessed, but tools to facilitate risk assessment need to be developed.
authors: Department of Health Promotion and Education, School of Public Health, 24951 North Circle Drive, Loma Linda, CA 92354, USA. stonstad@llu.edu
authors: Serena
authors: S
authors: Tonstad
authors: Jean-Pierre
authors: JP
authors: Després
mesh_terms: D050197:Atherosclerosis / Q000209:etiology / Q000517:prevention & control; D050110:Bariatric Surgery; D003131:Combined Modality Therapy; D050171:Dyslipidemias / Q000188:drug therapy / Q000209:etiology / Q000601:surgery / Q000628:therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008019:Life Style; D009765:Obesity / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D015431:Weight Loss
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents